Leerink Partners Remains Bullish as Fate Therapeutics (FATE) Plans to Initiate ProTmune Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Fate Therapeutics (FATE) Tops Q4 EPS by 1c
March 3, 2016 4:15 PM ESTFate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $580 thousand.
Cash and cash equivalents as of December 31, 2015 were $64.8 million, compared to $49.1 million as of December... More
Trading Radar for 3/3: Barnes & Noble (BKS), Ciena (CIEN), HP Enterprise (HPE), H&R Block (HRB), Trina Solar (TSL) Report
March 2, 2016 3:00 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EST
Earnings:
Ability, Inc. (Nasdaq: ABIL) - consensus EPS $0.09
Agenus (Nasdaq: AGEN) - consensus loss $0.17
Alaska Communications Systems (Nasdaq: ALSK) - consensus loss $0.01
Ameresco (Nasdaq:... More
